Vaccination programs have had a central role in the global struggle against the Covid-19 disease since the first days of the pandemic. Governments have worked in tandem with healthcare agencies as well as pharmaceutical companies all over the globe to deliver vaccines and vaccinate the people who badly need protection. However, the continued vaccination hesitancy and vaccine inequality in some parts of the world have yet to be addressed. At the same time, the painstaking struggle of governments, healthcare organizations, health workers, and pharmaceutical companies against the pandemic has been laudable; the disappointing issues of vaccine hesitation and non-uniform access to vaccines worldwide limit an efficient containment of the pandemic.
Despite the positive outcomes of the global vaccination programs, it is evident that there are cases when the planning and execution of the campaign lead to hiccups.
Though many accomplishments were achieved, hurdles still stand in the way of vaccine distributional justice between the nation and the world. As the most deprived states still lag in purchasing the required vaccine quantity, health inequalities worsen. COVAX, a platform that assists in distributing vaccines globally, is crucial in solving this problem. So, rich countries, increased production, and even access to vaccines despite pharmaceutical companies’ influence all need to be urgently addressed (Eccleston-Turner & Upton, 2021). The complexities in distribution, such as the cold chain necessities and the gloominess in achieving the remote areas and the marginalized population, are associated.
Routine surveillance of everything concerning vaccine distribution and placement will be made, depending on the necessity that might prevail and on the most vulnerable populations. Through examining the matters stated, people can progress towards providing the initial steps toward vaccine application everywhere in the world and stop the COVID-19 pandemic on a worldwide scale.
Assessment of Different Vaccines and the Mark that they’ve Made.
Among vaccines, some like Sinovac and Sinopharm are widely applied in some areas and demonstrate their power in mitigation the severe disease and hospitalization. In contrast with traditional methods that have remained unchanged over the past many years, modern techniques, such as protein subunit vaccines, are more sophisticated. Vaccines like Sanofi and GSK protein subunit vaccine have shown themselves to be as effective as the RNA vaccine (Mohsen Heidary et al., 2022). Each vaccine vaccine possesses a combination of unique features that can collectively tackle the manmade variety and logistical limitations thus offering the effective diversity proof for the need of a diversified vaccine portfolio against the pandemic.
Accordingly, all efforts are directed toward developing better vaccines and/or booster shots that can address newly arising clones, thus making the protection durable against severe threats longer.
Exploration of the Factor of Vaccine Hesitancy and Strategies to Conquer it.
On the part of the healthcare policymakers, there is the need to form a taskforce of all the key stakeholders to the challenge of vaccine reluctance and hesitance. By combining a wide variety of communication channels like social media, mass media and participation programs, it can be possible to involve different groups of the society and address their respective problems (Strully & al., 2021). Even more, pinpointing and addressing socioeconomic determinants help us win the vaccination hesitancy fight. It includes removing barriers like the mobility of goods, language communication, and vaccination.
Dissemination of community-specific target programs, those tailored to address vaccine accessibility issues, is likely to result in an equal distributing and uptake pattern. As a result, cooperation with and engaging confidence of reliable local authorities and opinion shapers will make vaccination confident sound louder.
Conclusion
Vaccination programs have demonstrated their unprecedented efficacy in containing the outbreak of COVID-19 globally. Hurdles such as vaccine hesitance and inequitable distribution are still emergencies. As a result, individuals and governments may counter these issues through the vaccine equity increase, misinformation defeat, as well as goals- oriented communications, thus reaching the point of broad immunization traffic and, consequently, the end of the COVID-19 pandemic.
References
Addressing common barriers in adult immunizations: a review of interventions. (2019). Expert Review of Vaccines. https://www.tandfonline.com/doi/abs/10.1080/14760584.2019.1698955
Eccleston-Turner, M., & Upton, H. (2021). International Collaboration to Ensure Equitable Access to Vaccines for COVID‐19: The ACT‐Accelerator and the COVAX Facility. The Milbank Quarterly, 99(2), 426–449. https://doi.org/10.1111/1468-0009.12503
Mohsen Heidary, Vahab Hassan Kaviar, Shirani, M., Roya Ghanavati, Moloudsadat Motahar, Sholeh, M., Hossein Ghahramanpour, & Saeed Khoshnood. (2022). A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.927306
Strully, K. W., Harrison, T. M., Pardo, T. A., & Carleo-Evangelist, J. (2021). Strategies to Address COVID-19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations. Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.6452681
write